Study of Hemostasis During the Atrial Fibrillation Ablation Procedure

Study of Hemostasis During the Atrial Fibrillation Ablation Procedure

Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial fibrillation) was interrupted a few days before the procedure in order to limit the risk of per-procedural bleeding. However, 3 recent randomized studies concerning the 3 DOACs available suggest that treatment should not be interrupted during the entire operative period. The operation therefore takes place under double anticoagulation with a direct oral anticoagulant and unfractionated heparin. Under these conditions, ACT monitoring can no longer be considered a reliable means of measuring the level of anticoagulation. It was therefore necessary to explore the hemostasis of these patients in a broad way in order to avoid any risk of overdose of UFH (Unfractionated Heparin) during the procedure.

Inclusion Criteria:

• Patients over 18 years-old
• with an atrial fibrillation
• Operated for an atrial fibrillation procedure in the University hospital of Strasbourg
• Without interruption of the direct oral anticoagulant
• For whom extended biological assessment has been made in routine practice

Exclusion Criteria:

• Patients who refused the use of their data for this study